Privacy

Cookie Policy

Contact

Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

HomeFDAHistoSonics Receives FDA "Breakthrough Device Designation" for Novel Sonic Beam Therapy

HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy

Breakthrough status for new histotripsy targeted liver therapy will help provide timely access to non-invasive liver treatment

MARKET REPORTS

United States Cardiovascular Devices Market 2021-2027

United States Cardiovascular Devices Market is projected to reach US$ 39.98 Billion by 2027 from US$ 25.34 Billion in 2020, growing with a CAGR of 6.73%

Global Cerebrospinal Fluid Drainage Catheter Market (2021 to 2027) – by Application, Type and Regional Outlook

The Global Cerebrospinal Fluid Drainage Catheter Market size is expected to reach $402.6 Million by 2027, rising at a market growth of 8.6% CAGR during the forecast period. For the treatment of hydrocephalus, placement of cerebral spinal fluid (CSF) shunt systems is becoming a common medical and life-saving procedure for the majority of the patients.

United States Insulin Delivery Devices Market Report 2021

This new report provides an in-depth assessment of the U.S insulin delivery devices market dynamics, opportunities, future road-map, competitive landscape and discusses major trends.

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

HistoSonics the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform. Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy and liquefy tissue in the liver without incisions, ionizing radiation or heat.

“The Breakthrough Device Designation is a significant milestone for our company and validates our belief that our platform offers significant advantages over existing approved or cleared alternatives, per FDA requirements,” said Mike Blue, President and CEO of HistoSonics. “Early and ongoing clinical results are promising and suggest that our ability to precisely destroy targeted liver tissue, completely non-invasively, and without the challenges associated with ionizing radiation or other locoregional therapies, provides advantages to patients and physicians that don’t exist today, and we look forward to working with the FDA to make the technology accessible as quickly as possible.”

The company believes the novel mechanism of action of their proprietary technology may offer significant advantages to patients, including equivalent treatment effect throughout the entire treatment volume resulting in precise and predictable treatment zones. Early clinical and pre-clinical results also suggest that histotripsy largely preserves critical structures such as the liver capsule, and larger vessels and ducts within or adjacent to the treated volume of tissue. Additionally, histotripsy enables the treating physicians the ability to monitor the destruction of tissue under continuous real time visualization and control, unlike any modality that exists today. The Breakthrough Designation will allow the company to engage with the FDA in a prioritized review during the regulatory market authorization process.

HistoSonics has worked cooperatively with the FDA for over 3 years in developing pre-clinical and clinical data required for regulatory market authorization and intends to continue collaborating with the Agency throughout the ongoing Investigational Device Exemption (IDE) Study, #HOPE4LIVER US, which is designed to evaluate the safety and technical efficacy of histotripsy in patients with primary and secondary liver tumors. The company plans to share US and European #HOPE4LIVER Study data and results with FDA to demonstrate the benefits of histotripsy in a broad patient population.

The HistoSonics System is investigational and is not available for sale in the United States or Europe. It is limited to investigational use in the approved IDE and European studies.

spot_img

DON'T MISS

Roam Robotics Launches Partnership with the San Francisco VA Health Care System

Ascend, from Roam Robotics, leverages robotics and proprietary algorithms to improve mobility and dramatically improve daily life for those experiencing knee pain.

Saranas® Announces Initial Enrollment of SAFE-MCS Clinical Trial

The first patient was enrolled at Atlantic Health System’s Morristown Medical Center in Morristown, NJ, by Dr. Philippe Généreux, Co-Director of the Structural Heart Program, and Dr. Dimitrios Karmpaliotis, Medical Director of the Cardiovascular Rescue and Recovery Program and the Advanced Coronary Therapeutics and Chronic Total Occlusions Program, at Morristown Medical Center.

Cancer Patients Overlooked in COVID-19 Vaccine Rollout

For the new study, researchers sought to determine the proportion of states that elected to follow CDC recommendations. They identified every states’ COVID vaccination webpage through keyword-based internet search and set out to identify information about vaccination for cancer patients.

MRI Reveals Altered Brain Structure in Fetuses Exposed to Alcohol

For the study, researchers recruited 500 pregnant women who were referred for a fetal MRI for clinical reasons. On an anonymous questionnaire, 51of the women admitted to consuming alcohol during their pregnancy.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy